https://scholars.lib.ntu.edu.tw/handle/123456789/561790
Title: | Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients | Authors: | YU-SEN HUANG JENNY LING-YU CHEN Feng-Ming Hsu JEI-YIE HUANG WEI-CHUN KO Chen, Y.-C. FU-SHAN JAW RUOH-FANG YEN YEUN-CHUNG CHANG |
Issue Date: | 2018 | Journal Volume: | 47 | Journal Issue: | 1 | Start page/Pages: | 191-199 | Source: | Journal of Magnetic Resonance Imaging | Abstract: | Purpose: To evaluate the response in patients undergoing SBRT using dynamic contrast-enhanced (DCE) integrated magnetic resonance positron emission tomography (MR-PET). Stereotactic body radiation therapy (SBRT) is efficacious as a front-line local treatment for non-small cell lung cancer (NSCLC). Materials and Methods: We prospectively enrolled 19 lung tumors in 17 nonmetastatic NSCLC patients who were receiving SBRT as a primary treatment. They underwent DCE-integrated 3T MR-PET before and 6 weeks after SBRT. The following image parameters were analyzed: tumor size, standardized uptake value (SUV), apparent diffusion coefficient, Ktrans, kep, ve, vp, and iAUC60. Chest computed tomography (CT) was performed at 3 months after SBRT. Results: SBRT treatment led to tumor changes including significant decreases in the SUVmax (–61%, P < 0.001), Ktrans mean (–72%, P = 0.005), Ktrans standard deviation (SD; –85%, P = 0.046), kep mean (–53%, P = 0.014), kep SD (–63%, P = 0.001), and vp SD (–58%, P = 0.002). The PET SUVmax was correlated with the MR kep mean (P = 0.002) and kep SD (P < 0.001). The percentage reduction in Ktrans mean (P < 0.001) and kep mean (P = 0.034) at 6 weeks post-SBRT were significantly correlated with the percentage reduction in tumor size, as measured using CT at 3 months after SBRT. Univariate analyses revealed a trend toward disease progression when the initial SUVmax > 10 (P = 0.083). Conclusion: In patients with NSCLC who are receiving SBRT, DCE-integrated MR-PET can be used to evaluate the response after SBRT and to predict the local treatment outcome. Level of Evidence: 2. Technical Efficacy: Stage 1. J. Magn. Reson. Imaging 2018;47:191–199. ? 2017 International Society for Magnetic Resonance in Medicine |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/561790 | ISSN: | 1053-1807 | DOI: | 10.1002/jmri.25758 | SDG/Keyword: | adult; aged; Article; cancer radiotherapy; clinical article; clinical evaluation; computer assisted tomography; dynamic contrast-enhanced magnetic resonance imaging; female; human; male; non small cell lung cancer; patient assessment; positron emission tomography; priority journal; radiation dose fractionation; radiation response; stereotactic body radiation therapy; thorax radiography; treatment outcome; treatment planning; tumor volume; area under the curve; chemistry; disease exacerbation; disease free survival; follow up; image processing; lung tumor; middle aged; multimodal imaging; non small cell lung cancer; nuclear magnetic resonance imaging; positron emission tomography; prospective study; radiosurgery; very elderly; x-ray computed tomography; contrast medium; fluorodeoxyglucose f 18; radiopharmaceutical agent; Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Contrast Media; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Tomography, X-Ray Computed; Treatment Outcome |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.